For an atypical meningioma WHO grade 2 s/p GTR, do molecular findings that suggest an integrated diagnosis of a grade 3 tumor change adjuvant radiation treatment recommendations?

Topics: Radiation Oncology • Neuro-Oncology

Molecular findings that indicate a more aggressive WHO grade 2 meningioma would certainly support recommendations for adjuvant RT after GTR, but if these tumors have a prognosis similar to grade 3, then should the RT dose and/or treatment volumes follow guidelines for a WHO grade 3 tumor (ie higher dose, bigger margins) or should the dose/volume remain the same as for any WHO grade 2 tumor?

Answer from: Radiation Oncologist at Academic Institution

There is no definitive clarity on this question, as the data simply do not exist. Therefore, decision-making has to be individualized. For residual disease, the GTV would be easy to estimate, but it might be prudent to utilize the pre-op scans in these patients to understand the pre-op GTV, which co...

Comments

Radiation Oncologist at University of Arizona
The patient illustrated in this question is clearl...

Answer from: Radiation Oncologist at Academic Institution

61.2/34

Related Questions